Avita Medical highlights data from real-world analysis of RECELL

AVITA Medical (RCEL) highlighted data presented by researchers at the British Burn Association Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents the largest real-world analysis of skin cell suspension autograft to date. The patented RECELL technology uses a small sample of a patient’s own skin to produce Spray-On Skin Cells, an autologous cell suspension that supports wound healing throughout the wound bed. Compared to traditional skin grafting, RECELL requires significantly less donor skin and offers a range of clinical benefits, including less pain at the donor site, faster healing, improved outcomes, and fewer procedures. These advantages contribute to shorter hospital stays and associated cost savings. The retrospective study, presented by Jeffrey E. Carter, MD, FACS, FABA, of Louisiana State University Health and Sciences Center and University Medical Center in New Orleans, analyzed registry data from over 6,300 patients treated with RECELL between 2019 and 2024. Key findings from patients with burns covering less than 30% total body surface area include: Significant reduction for length of stay for patients treated with RECELL Spray-On Skin Cells alone by 6.2 days or 35.7% compared to those with split-thickness autografts; Cost savings of approximately $300 million over the 5-year study period, driven by reduced length of stay.